Bacillus subtilis MB40 and No Significant Adverse Effects or Microbiome Disruption

• Probiotic for pathogen-specific Staphylococcus aureus decolonisation in Thailand: a phase 2, double-blind, randomised, placebo-controlled trial.

  • 2023-02
  • RCT · n = 115
  • The Lancet. Microbe 4(2)
  • • Pipat Piewngam
    • Sunisa Khongthong
    • Natthrit Roekngam
    • Yongyuth Theapparat
    • Somkiat Sunpaweravong
    • Damrongsak Faroongsarng
    • Michael Otto

  • PubMed: 36646104
  • DOI: 10.1016/s2666-5247(22)00322-6

  2 Insights on

  • No Significant Adverse Effects or Microbiome Disruption

  • High evidence
  • Large Human Trial

  There were no differences in adverse effects or significant microbiome changes between the intervention and placebo groups.

  Effect

  Beneficial

  Effect size

  Small

  Significant

  No